Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS FARMA
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
To compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study are being treated with salmeterol /fluticasone propionate Studio per confrontare l'efficacia e la sicurezza di indacaterolo con salmeterolo / fluticasone propionato nel trattamento di pazienti con con broncopneumopatia cronica ostruttiva di grado moderato
To compare the effectiveness and safety of indacaterol with salmeterol /fluticasone propionate treatment in patients with moderate chronic obstructive pulmonary disease who, on entry to the study ar...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
A phase II study to evaluate the efficacy and safety of the investigational compound AUY922 in combination with trastuzumab as second-line treatment in patients with HER2-positive advanced gastric cancer Studio di fase II per valutare l'efficacia e la sicurezza di AUY922 in associazione con trastuzumab come trattamento di seconda linea nei pazienti con carcinoma gastrico HER2-positivo in stadio avanzato
To assess the preliminary efficacy of AUY922 in combination with trastuzumab standard therapy, using Objective Response Rate (ORR), as per investigator, in advanced HER2+ gastric cancer patients pro...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study)
The primary objective of the study is to compare the 6-month cumulative incidence of the safety composite endpoint of wound healing complications related to initial transplant surgery, pleural/pericar...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients
Primary objective(s) To evaluate the pharmacokinetics of AEB071 and primary metabolite, AEE800, in liver transplant patients in the immediate post transplant period To evaluate the safety and tole...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 5 ans
efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias in Parkinson's patients with moderate to severe L-dopa induced dyskinesias l’efficacia, la sicurezza e la tollerabilita' di AQW051 nella riduzione delle discinesie indotte da L-dopa in pazienti affetti da malattia di Parkinson con discinesie indotte da L-dopa da moderate a severe
• To assess the anti-dyskinetic efficacy of multiple doses of AQW051 in Parkinson's patients with moderate to severe L-dopa induced dyskinesias using the modified Abnormal Involuntary Movement Scale...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
4
5
6
7
8
9